<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438932</url>
  </required_header>
  <id_info>
    <org_study_id>2005P000486</org_study_id>
    <nct_id>NCT00438932</nct_id>
  </id_info>
  <brief_title>Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease</brief_title>
  <official_title>Reduced Phosphate Intake in &quot;Normo-Phosphatemic&quot; Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how the kidneys control the blood levels of
      phosphorus in patients with early chronic kidney disease. The ultimate goal is to use this
      information to design improved treatment strategies for phosphorus-related problems for the
      millions of patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phosphorus is a mineral found in dairy products, nuts, and meat that is essential for bone
      health and many other important functions inside the body's cells. The kidneys are
      responsible for keeping the blood levels of phosphorus normal. Healthy kidneys do this by
      spilling excess phosphorus into the urine. In patients with chronic kidney disease, the
      kidneys are unable to spill an adequate amount of phosphorus so that excess phosphorus can
      accumulate in the walls of blood vessels leading to heart disease, their leading cause of
      death. A recently discovered hormone called FGF-23 helps control the blood levels of
      phosphorus by &quot;telling&quot; the kidney how much phosphorus to spill in the urine. The purpose of
      this study is to learn more about how FGF-23 helps the kidneys control the blood levels of
      phosphorus. The ultimate goal is to use this information to design improved treatment
      strategies for phosphorus-related problems for the millions of patients with chronic kidney
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroblast Growth Factor 23 (FGF-23)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Plasma FGF-23 was measured using c-terminal FGF23 assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour Urinary Phosphate</measure>
    <time_frame>2 weeks</time_frame>
    <description>from 24-hr urine collections</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Lanthanum Carbonate and Low Phosphorus Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% of subjects will receive binders plus a phosphate restricted diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanthanum Carbonate and Unrestricted Phosphorus Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% binders + unrestricted phosphate diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Low Phosphorus Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% placebo + phosphate restricted diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Unrestricted Phosphorus Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% placebo + unrestricted phosphate diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum Carbonate</intervention_name>
    <description>Lanthanum carbonate 1000mg 3x/day</description>
    <arm_group_label>Lanthanum Carbonate and Low Phosphorus Diet</arm_group_label>
    <arm_group_label>Lanthanum Carbonate and Unrestricted Phosphorus Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Phosphorus Diet</intervention_name>
    <description>Low phosphorus diet will consist of 800 mg of phosphorus per day.</description>
    <arm_group_label>Lanthanum Carbonate and Low Phosphorus Diet</arm_group_label>
    <arm_group_label>Placebo and Low Phosphorus Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Unrestricted Phosphorus Diet</intervention_name>
    <description>Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
    <arm_group_label>Lanthanum Carbonate and Unrestricted Phosphorus Diet</arm_group_label>
    <arm_group_label>Placebo and Unrestricted Phosphorus Diet</arm_group_label>
    <other_name>Neutraphos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lanthanum Carbonate placebo given three times a day with meals.</description>
    <arm_group_label>Placebo and Low Phosphorus Diet</arm_group_label>
    <arm_group_label>Placebo and Unrestricted Phosphorus Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with stage 3a, 3b and 4 CKD

          -  subjects have to be aged 18 years or older

          -  subjects have to have normal serum phosphate levels (&lt; 4.6 mg/dl)

          -  subjects have to have sufficient 25-OH Vit0amin D levels (≥ 20 ng/ml)

        Exclusion Criteria:

          -  subjects with rapidly advancing renal failure who thus might develop hyperphosphatemia
             or end stage renal disease requiring initiation of dialysis during the study period

          -  subjects expected to require dialysis initiation within the follow up period

          -  subjects with hyperphosphatemia &gt; 4.6 mg/dL

          -  subjects with any previous or current treatment with phosphate binders or active
             vitamin D (doxercalciferol or calcitriol)

          -  subjects with malnutrition, defined as a serum albumin &lt; 3.0 mg/dl, in order to avoid
             worsening protein-malnutrition status during the restricted study period since
             phosphate restricted diets are also low in protein

          -  subjects with chronic gastrointestinal diseases that could impede their absorptive
             ability such as Crohn's disease, ulcerative colitis and sprue

          -  subjects with liver disease (ALT or AST &gt; 100 U/L) or cholestasis (direct bilirubin &gt;
             1.0 mg/dl) because this can limit their ability to absorb fat soluble vitamins such as
             vitamin D

          -  subjects with anemia, defined as a hematocrit &lt;27% at the screening visit

          -  subjects wht have been hospitalization within the previous 4 weeks

          -  subjects who are pregnant

          -  subjects who are breastfeeding mothers

          -  subjects with primary hypoparathyroidism

          -  subjects with primary hyperparathyroidism

          -  subjects with previous subtotal parathyroidectomy

          -  subjects with previous outpatient counseling by a renal nutritionist

          -  subjects who are unable to independently provide written informed consent - prisoners,
             mentally incompetent, minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myles Wolf, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Miami Miller School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Jueppner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011 Feb;26(2):584-91. doi: 10.1093/ndt/gfq419. Epub 2010 Jul 14.</citation>
    <PMID>20631407</PMID>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>September 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2011</results_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Myles S. Wolf</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>phosphate, phosphorus, FGF-23, PTH, 1,25D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16 patients completed the full study. Patients were recruited from renal clinics.</recruitment_details>
      <pre_assignment_details>There was no wash-out, run in or transition.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lanthanum Carbonate &amp; Low Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="P2">
          <title>Lanthanum Carbonate &amp; Unrestricted Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
        <group group_id="P3">
          <title>Placebo &amp; Low Phosphorous Diet</title>
          <description>Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="P4">
          <title>Placebo &amp; Unrestricted Phosphorous Diet</title>
          <description>Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lanthanum Carbonate &amp; Low Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="B2">
          <title>Lanthanum Carbonate &amp; Unrestricted Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
        <group group_id="B3">
          <title>Placebo &amp; Low Phosphorous Diet</title>
          <description>Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="B4">
          <title>Placebo &amp; Unrestricted Phosphorous Diet</title>
          <description>Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11"/>
                    <measurement group_id="B2" value="62" spread="13"/>
                    <measurement group_id="B3" value="56" spread="21"/>
                    <measurement group_id="B4" value="68" spread="17"/>
                    <measurement group_id="B5" value="62" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibroblast Growth Factor 23 (FGF-23)</title>
          <description>Plasma FGF-23 at the baseline visit was measured using C-terminal FGF23 assay.</description>
          <units>Ru/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.3" spread="110.9" lower_limit="77" upper_limit="252"/>
                    <measurement group_id="B2" value="263.1" spread="167.9" lower_limit="158" upper_limit="368"/>
                    <measurement group_id="B3" value="178.8" spread="97.6" lower_limit="103" upper_limit="254"/>
                    <measurement group_id="B4" value="121.8" spread="60.0" lower_limit="85" upper_limit="158"/>
                    <measurement group_id="B5" value="182.0" spread="116.3" lower_limit="95" upper_limit="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hr urine phosphate</title>
          <description>measured from 24 hour urine collections; 2 separate collections were obtained; values are means of the two collections; pre-intervention</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="659.0" spread="269.8" lower_limit="491" upper_limit="827"/>
                    <measurement group_id="B2" value="761.8" spread="77.4" lower_limit="704" upper_limit="820"/>
                    <measurement group_id="B3" value="745.4" spread="287.0" lower_limit="503" upper_limit="988"/>
                    <measurement group_id="B4" value="934.6" spread="545.5" lower_limit="607" upper_limit="1262"/>
                    <measurement group_id="B5" value="775.2" spread="320.0" lower_limit="564" upper_limit="889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fibroblast Growth Factor 23 (FGF-23)</title>
        <description>Plasma FGF-23 was measured using c-terminal FGF23 assay.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate &amp; Low Phosphorous Diet</title>
            <description>Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.</description>
          </group>
          <group group_id="O2">
            <title>Lanthanum Carbonate &amp; Unrestricted Phosphorous Diet</title>
            <description>Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
          </group>
          <group group_id="O3">
            <title>Placebo &amp; Low Phosphorous Diet</title>
            <description>Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; Unrestricted Phosphorous Diet</title>
            <description>Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibroblast Growth Factor 23 (FGF-23)</title>
          <description>Plasma FGF-23 was measured using c-terminal FGF23 assay.</description>
          <units>RU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.695" spread="56.170737"/>
                    <measurement group_id="O2" value="297" spread="77.69778"/>
                    <measurement group_id="O3" value="188.975" spread="60.2020815"/>
                    <measurement group_id="O4" value="143.7675" spread="37.507486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Urinary Phosphate</title>
        <description>from 24-hr urine collections</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lanthanum Carbonate &amp; Low Phosphorous Diet</title>
            <description>Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.</description>
          </group>
          <group group_id="O2">
            <title>Lanthanum Carbonate &amp; Unrestricted Phosphorous Diet</title>
            <description>Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
          </group>
          <group group_id="O3">
            <title>Placebo &amp; Low Phosphorous Diet</title>
            <description>Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; Unrestricted Phosphorous Diet</title>
            <description>Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Urinary Phosphate</title>
          <description>from 24-hr urine collections</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.4" spread="49.3063045"/>
                    <measurement group_id="O2" value="382.725" spread="7.0577825"/>
                    <measurement group_id="O3" value="346.8" spread="132.671329"/>
                    <measurement group_id="O4" value="830.25" spread="220.003449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lanthanum Carbonate &amp; Low Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="E2">
          <title>Lanthanum Carbonate &amp; Unrestricted Phosphorous Diet</title>
          <description>Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
        <group group_id="E3">
          <title>Placebo &amp; Low Phosphorous Diet</title>
          <description>Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.</description>
        </group>
        <group group_id="E4">
          <title>Placebo &amp; Unrestricted Phosphorous Diet</title>
          <description>Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In addition to limited power, the small sample size led to imbalances in baseline laboratory tests, which added further variability to the analyses. .</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tamara Isakova, MD, MMSc</name_or_title>
      <organization>University of Miami Miller School of Medicine</organization>
      <phone>305-243-4374</phone>
      <email>tisakova@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

